ELV
Elevance Health, Inc.
$430.23
+0.46% 2026-10-19
Health CareS&P 500
ELVSPY
1W
+1.9%
1M
+4.7%
3M
+13.0%
6M
+35.9%
YTD
+24.5%
1Y
+25.8%
Grades vs sector
Momentum59th pct in sectorB-
Momentum
59th pct in sector
12-1 return: +25.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth16th pct in sectorD-
Growth
16th pct in sector
Revenue growth (YoY): +1.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value71st pct in sectorB
Value
71st pct in sector
Forward E/P: 6.9% · EBITDA/EV: 9.6%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability42nd pct in sectorC
Profitability
42nd pct in sector
Profit margin: +2.5% · Return on equity: +11.1%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
rank 162 of 499 · 12-1 momentum % 23.4
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$93.3B
P/E (trailing)19.0
P/E (forward)14.5
52-week range274.84 – 436.24
Revenue growth (YoY, latest qtr)+1.4%
Dividend yield1.61%
Analyst consensusBuy (21)
Mean price target$451.71 (+5%)
Valuation & fundamentals
Bottom line
Looks undervalued
Model read-out from the numbers below, not advice. Score +3 (DCF counts double).
▲DCF (base case)above the price by 55%
▲Forward P/E vs sector14.5x vs median 17.6x
•Piotroski F-score5/9
▲Altman Z3.0 (safe)
▲Net debt / EBITDA-0.7x
•Analyst target+5% (21 analysts)
Discounted cash flow
Bear
$408
-5%
growth -0% · disc. 8.8% · term. 2.0%
Base
$666
+55%
growth 5% · disc. 7.8% · term. 2.5%
Bull
$1,075
+150%
growth 8% · disc. 6.8% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price implies shrinking cash flows: about -2% a year for 10 years.
Implied
-2%/yr
FCF, last 3 yrs
-24%/yr
FCF, last 5 yrs
-20%/yr
Revenue, last 3 yrs
+8%/yr
Revenue, last 5 yrs
+10%/yr
Same inputs as the DCF above: trailing free cash flow 6.3B, 7.8% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.71 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 22nd pct
19.0×cheaper
Forward P/E
cheaper
sector median 17.6× · 36th pct
14.5×cheaper
EV / EBITDA
cheaper
sector median 15.8× · 29th pct
12.7×cheaper
Price / sales
cheaper
sector median 3.1× · 7th pct
0.5×cheaper
Price / book
cheaper
sector median 3.5× · 23rd pct
2.1×cheaper
FCF yield
cheaper
sector median 4.1% · 82nd pct
6.7%cheaper
Forward EPS $29.60 vs trailing $22.59 (+31% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
89.1%
Operating margin
2.7%
FCF margin
3.1%
Net margin
2.5%
Return on equity
11.1%
Return on invested capital
11.5%
Net debt / EBITDA
-0.7×
Current ratio
1.5×
Interest cover
3.8×
Cash conversion (OCF/NI)
1.5×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✗ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 3.0 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$452
+5%
Analysts
21
Buy
Range
$393–$492
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $199.1B | $5.7B | $3.2B |
| 2024 | $177.0B | $6.0B | $4.6B |
| 2023 | $171.3B | $6.0B | $6.8B |
| 2022 | $156.6B | $5.9B | $7.2B |
| 2021 | $138.6B | $6.2B | $7.3B |
| 2020 | $121.9B | $4.6B | $9.7B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +8.3%.
Earnings
Next report: 2026-10-21 · before open · EPS est 4.69
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-15 | 6.21 | 7.45 | +20.0% |
| 2026-04-22 | 10.81 | 12.58 | +16.4% |
| 2026-01-28 | 3.09 | 3.33 | +7.6% |
| 2025-10-21 | 4.94 | 6.03 | +22.0% |
| 2025-07-17 | 8.92 | 8.84 | -0.9% |
| 2025-04-22 | 11.48 | 11.97 | +4.3% |
| 2025-01-23 | 3.85 | 3.84 | -0.3% |
| 2024-10-17 | 9.65 | 8.37 | -13.3% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $50.5B | +1.4% |
| 2026-03-31 | $50.2B | – |
| 2025-12-31 | $49.7B | – |
| 2025-09-30 | $50.7B | – |
| 2025-06-30 | $49.8B | – |
Analyst actions
Guggenheim
PT $460
2026-10-12 · main
Buy → BuyPT $460
Barclays
PT $469
2026-10-07 · main
Overweight → OverweightPT $469
Bernstein
PT $488
2026-07-17 · main
Outperform → OutperformPT $488
Leerink Partners
PT $395
2026-07-17 · main
Market Perform → Market PerformPT $395
RBC Capital
PT $424
2026-07-16 · main
Sector Perform → Sector PerformPT $424
Wells Fargo
PT $473
2026-07-16 · main
Overweight → OverweightPT $473
Recent dividends
2026-09-10: $1.720 · 2026-06-10: $1.720 · 2026-03-10: $1.720 · 2025-12-05: $1.710 · 2025-09-10: $1.710 · 2025-06-10: $1.710 · 2025-03-10: $1.710 · 2024-12-05: $1.630
Insider trades
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
Stats refreshed 2026-10-19 19:19:43 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.